BioLegend is completely committed to the quality of science, as well as its advancement. This agreement is another step in our ongoing efforts to support the scientific community – said Gene Lay, President and CEO, BioLegend.
(PRWEB) May 02, 2014
The ability to reproduce published results is key for scientific progress. However, recent studies have reported that many published results cannot be independently reproduced. To examine this issue, the Cancer Biology Reproducibility Project is independently replicating 50 recent high impact cancer biology studies using the Science Exchange network of expert scientific labs. With a large team of researchers, the initiative will replicate directly the key result from a defined sample of studies. Across studies, the following will be evaluated: the feasibility of conducting direct replications, success in obtaining materials and procedures in order to conduct a direct replication, the rate of replication success, and covariates of replication success. The findings will be submitted and published in the open access journal PLoS ONE.
BioLegend will support the Cancer Biology Reproducibility Project by providing $100,000 in reagents and supplies from the BioLegend catalog, including antibodies for flow cytometry, functional antibodies, ELISAs, recombinant proteins, viability dyes, and other accessory reagents.
"BioLegend is completely committed to the quality of science, as well as its advancement. This agreement is another step in our ongoing efforts to support the scientific community," said Gene Lay, President and CEO, BioLegend.
"The generous donation of high-quality reagents provided by BioLegend will greatly benefit the Cancer Biology Reproducibility Project," said Dr. Elizabeth Iorns, Director of the Reproducibility Initiative and CEO of Science Exchange. "The money saved by the donation of these reagents will enable us to perform additional experiments from the studies selected, which will allow the generation of a more comprehensive replication dataset to study cancer biology reproducibility."
BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services, including assay development, sample testing, and conjugation. BioLegend was incorporated in June 2002 with headquarters in San Diego, CA. For more information on BioLegend, visit: http://www.biolegend.com.